Skip to main content

Day: July 12, 2022

Gilat to Report Second Quarter 2022 Results on August 9th

PETAH TIKVA, Israel, July 12, 2022 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, today announced that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022. Conference Call and WebcastFollowing the release, Adi Sfadia, Chief Executive Officer, and Gil Benyamini, Chief Financial Officer, will discuss Gilat’s second quarter 2022 results and business achievements and participate in a question and answer session: Date: Tuesday, August 9, 2022Start: 09:30 AM EDT / 16:30 IDTDial-in: US: 1-866-744-5399  International: +972-3-918-0609A simultaneous webcast of the conference call will be available on the Gilat website at www.gilat.com and through this link: https://Veidan.activetrail.biz/gilatq2-2022 The...

Continue reading

OTC Markets Group Welcomes Cryomass Technologies Inc. to OTCQX

NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Cryomass Technologies Inc. (OTCQX: CRYM), a company preparing to manufacture and operate field-mobile equipment for the handling of harvested cannabis, hemp and other high-value plant material, has qualified to trade on the OTCQX® Best Market. Cryomass Technologies Inc. upgraded to OTCQX from the OTCQB® Venture Market. Cryomass Technologies Inc. begins trading today on OTCQX under the symbol “CRYM.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. The OTCQX Market provides investors with a premium U.S. public market to research and trade the shares of investor-focused companies....

Continue reading

Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)

Expected data in H2 2022 brings Synlogic to three clinical readouts this year Third candidate in less than two years to enter the clinic; Reflects productivity of Synthetic Biotic platform CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, announced today that it has dosed its first healthy volunteer in its Phase 1 study of the investigational oral therapy SYNB1353 designed to consume methionine for the potential treatment of homocystinuria (HCU). “We are delighted to continue to advance our pipeline of programs with today’s announcement, a notable milestone as we continue towards three expected clinical readouts in 2022, and a reflection of the...

Continue reading

Troilus Reports Metallurgical Recoveries of 95.5% Gold, 95.9% Copper and 92.8% Silver From Zone Z87 Pilot Plant Test Program

MONTREAL, July 12, 2022 (GLOBE NEWSWIRE) — Troilus Gold Corp. (TSX: TLG; OTCQX: CHXMF) (“Troilus” or the “Company”) is pleased to report excellent metallurgical recovery results for Zone 87 as part of the recently concluded pilot plant scale metallurgical testing program on each of the main mineral deposits (Zone 87, J Zone and Southwest Zone) from its Troilus Project in northcentral Quebec, Canada. Approximately 3 tonnes of sample material from each of the main mineral zones were sent to Eriez’s metallurgical test facility in Erie, Pennsylvania last year to validate the recovery of gold, copper and silver using standard gravity and column flotation technology. The latest Zone 87 results, along with the metallurgical recoveries for the Southwest and J zones announced earlier this year (see press releases from February 28 and June...

Continue reading

Nuwellis Initiates Its Outpatient Heart Failure Strategy Using Aquadex Ultrafiltration Therapy

MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on improving the quality of life for people with fluid overload, today announced key takeaways from its recent physician-led webinar discussing the benefits of treating fluid overloaded heart failure (HF) patients with Aquadex® ultrafiltration (UF) in the outpatient setting – the first step toward commercializing this opportunity. The webinar featured perspectives from leading heart failure clinicians from across the U.S.:Ramesh Emani, MD, Interventional Heart Failure Cardiologist and Associate Professor of Clinical Medicine, Division of Cardiology, The Ohio State University – Columbus, OH Detlef Wencker, MD, Advanced Heart Failure Specialists – Dallas, TX Pat Correlli, PA-C, Chief Outpatient Physician’s Associate and...

Continue reading

GXO Schedules Second Quarter 2022 Earnings Conference Call for Wednesday, August 3, 2022

GREENWICH, Conn., July 12, 2022 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), will hold its second quarter conference call and webcast on Wednesday, August 3, 2022, at 8:30 a.m. Eastern Time. The company’s results will be released after market close on Tuesday, August 2, 2022, and made available on investors.gxo.com at that time. August 2, 2022, marks the one-year anniversary of GXO’s debut on the New York Stock Exchange as the world’s largest pure-play contract logistics provider. Access information: Call toll-free from U.S./Canada: 877-407-8029 International callers: +1 201-689-8029 Conference ID: 13731429 Live webcast at: investors.gxo.com A replay of the conference call will be available until August 17, 2022, by calling toll-free (from U.S./Canada) 877-660-6853; international callers dial +1 201-612-7415. Use the passcode...

Continue reading

Plus Therapeutics Successfully Completes Key Milestone for cGMP Manufacture of Lead Investigational Radiotherapeutic

Completes technology transfer and initiates cGMP manufacturing for critical Rhenium-186 NanoLiposome (186RNL) drug product intermediate On track to manufacture cGMP materials to support ongoing and planned clinical trials for rare cancers in 2022 and beyond AUSTIN, Texas, July 12, 2022 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it has reached a key milestone on the path to commercialization of Rhenium-186 NanoLiposome (186RNL) as the Company completed the technology transfer and initiation of cGMP manufacturing of the 186RNL drug intermediate with Piramal Pharma Solutions (PPS). Additionally, the intermediate drug product is in stability testing and compliant...

Continue reading

GameOn Completes US$550,000 Loan

VANCOUVER, British Columbia, July 12, 2022 (GLOBE NEWSWIRE) — GameOn Entertainment Technologies Inc. (“GameOn” or the “Company”) (CSE: GET) (OTCQB: GMETF), a leading game technology company partnered with the world’s biggest IPs to launch, operate, and monetize web3 prediction and fantasy games, announces that, further to its press release dated July 4, 2022, it has entered into a loan agreement with Proje Ventures Inc. (“Proje”) whereby the Company has borrowed an aggregate of US$550,000 from Proje (the “Loan”). The Company intends to use the proceeds from the Loan for general working capital purposes. GameOn reported $207,151 in revenue in Q1, 2022, up from $2,791 in Q1, 2021. Management believes that the Company is on track to reach $1m in revenue in 2022, not including income from revenue share arrangements, and is on track...

Continue reading

Societal CDMO Announces Signing of Amendment to License and Supply Agreement With Lannett for Marketing of Verapamil PM and Verelan SR Products

Societal to Receive Greater Portion of Profit Sharing from Verapamil PM Product Sales Societal Awarded Potential New GMP Manufacturing Agreements for Multiple Additional Lannett Products SAN DIEGO and GAINESVILLE, Ga., July 12, 2022 (GLOBE NEWSWIRE) — Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has signed an amendment to its license and supply agreement with Lannett Company (“Lannett”) for the marketing of Verapamil PM and Verelan SR products. Under terms of the amendment, Societal will now receive improved overall economics, including a 10% increase in the profit share component of revenue from Verapamil PM product...

Continue reading

XPO Logistics Unveils RXO as Company Name for Planned Spin-Off

GREENWICH, Conn. , July 12, 2022 (GLOBE NEWSWIRE) — XPO Logistics, Inc. (NYSE: XPO), a leading provider of freight transportation services, today announced that a new company identity has been created in connection with the planned spin-off of its tech-enabled brokerage platform. The spin-off is named RXO to reflect the company’s commitment to provide reliability multiplied by outperformance. RXO will go to market with the tagline “Massive capacity. Cutting-edge technology.” XPO unveiled the new company’s identity on a landing page, RXO.com, where visitors can register to receive news about the spin-off’s upcoming milestones and leadership appointments.Brad Jacobs, chairman and chief executive officer of XPO Logistics, said, “Our spin-off now has a name — RXO — bringing it one step closer to becoming a standalone industry leader....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.